A number of investment brokers have recently updated their price targets on shares of Adamis Pharmaceuticals Corporation (ADMP). According to the latest broker reports outstanding on Monday 9th of May, 0 analysts have a rating of “strong buy”, 0 analysts “buy”, 0 analysts “neutral”, 0 analysts “sell” and 0 analysts “strong sell”.

Most recent broker ratings

03/29/2016 – Adamis Pharmaceuticals Corporation had its “buy” rating reiterated by analysts at Maxim Group. They now have a USD 17 price target on the stock.

05/29/2015 – Mizuho began new coverage on Adamis Pharmaceuticals Corporation giving the company a “buy” rating. They now have a USD 10 price target on the stock.

06/24/2014 – Adamis Pharmaceuticals Corporation had its “positive” rating reiterated by analysts at CRT Capital. They now have a USD 15 price target on the stock.

The share price of Adamis Pharmaceuticals Corporation (ADMP) was up +0.67% during the last day of trading, with a day high of 9.11. 106244 shares were traded during the last session.

The stock’s 50 day moving average is 7.25 and its 200 day moving average is 5.40. The stock’s market capitalization is 121.15M. Adamis Pharmaceuticals Corporation has a 52-week low of 3.05 and a 52-week high of 9.31.

View other investors thoughts on Adamis Pharmaceuticals Corporation with our new Stock Talk discussion platform. Sign up for free to contribute to the community and view research provided from other investors for any stock listed on the LSE, NYSE or NASDAQ.